▶ 調査レポート

世界の血液疾患治療市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Blood Disorder Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Blood Disorder Therapeutics  Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)「世界の血液疾患治療市場2022年-2027年:成長・動向・新型コロナの影響・市場予測」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2203A007
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、115ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥712,500 (USD4,750)▷ お問い合わせ
  Site Licence¥975,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,312,500 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社は、世界の血液疾患治療市場規模が、年平均6.2%成長すると予測しています。本市場調査レポートでは、血液疾患治療の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別(血漿由来因子、組換え因子、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、用途別(ヘモグロビンダイオスダー、血小板基礎疾患、血漿障害、骨髄増殖性疾患、遺伝性血液疾患)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の血液疾患治療市場規模:製品種類別(血漿由来因子、組換え因子、その他)
・世界の血液疾患治療市場規模:用途別(ヘモグロビンダイオスダー、血小板基礎疾患、血漿障害、骨髄増殖性疾患、遺伝性血液疾患)
・世界の血液疾患治療市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(Takeda Pharmaceutical Company Limited (Shire Plc)、Sanofi、Novo Nordisk A/S、…)
・市場機会・将来傾向

The Blood Disorder Therapeutics Market is expected to register a CAGR of 6.2% during the forecast period. Blood disorders are conditions that impact the blood’s ability to function correctly. It includes problems with the white blood cells, red blood cells, platelets, bone marrow, spleen, lymph nodes, and the proteins which are involved in bleeding and clotting (hemostasis and thrombosis). Most of the blood disorders are caused by mutations in specific genes and can be passed down in families. According to the National Heart, Lung, and Blood Institute, Hemophilia A is the most common type of the disease in males then females about 1 in 4,000 to 1 in 5,000 males worldwide are born with Hemophilia A disorder and Hemophilia B occurs in approximately 1 in 20,000 newborn males worldwide. As per study published in the PLOS Medicine Journal, sickle cell anemia cases are expected to increase about 30 percent globally by the year 2050. Rising prevalence of various blood disorders and increasing investment in research and development for advance treatment options are the key driving factors in blood disorder therapeutics market.

Key Market Trends

Recombinant Factors Segment is Expected to Hold a Significant Market Share in the Blood Disorder Therapeutics Market

  • Worldwide, the rising prevalence of blood disorders and increasing adoption of recombinant factor concentrates are the key drivers of the recombinant factors segment.
  • A recombinant factor is a form of blood factor that is manufactured via recombinant technology. Recombinant factors are used in the treatment of disorders such as hemophilia (prevention and control of hemorrhagic episodes).
  • According to the World Federation of Hemophilia Report, in the year 2017, worldwide around 315,423 people are affected by bleeding disorders. Among them approximately 196,706 people are living with Hemophilia, 76,144 people with von Willebrand disease (VWD) and 42,573 with other bleeding disorders. Furthermore, according to the National Hemophilia Foundation, approximately 75% of people with hemophilia around the world still do not receive adequate treatment or have no access to treatment.
  • Recombinant factors segment hold a significant market share by revenue and is anticipated to show steady growth over the forecast period due to the growing need to treat blood-related disorders and increase in production of recombinant products globally.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the blood disorder therapeutics market due to rising prevalence of various blood disorders and increasing awareness among the patient population in this region. According to the World Federation of Hemophilia, in the United States alone there are around 18 thousand people with hemophilia and over 11 thousand with von Willebrand disease. In addition, Hemophilia A affects 1 in 5,000 male births and approximately 400 babies are born with hemophilia A each year. Furthermore, increasing investments in research and development to develop treatment options for blood disorders and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Blood Disorder Therapeutics Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc, Amgen Inc and AstraZeneca Plc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Various Blood Disorders
4.2.2 Increasing Investment in R&D for Advance Treatment Options
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Stringent Regulations Norms
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Plasma Derived Factors
5.1.2 Recombinant Factors
5.1.3 Other Products
5.2 By Application
5.2.1 Hemoglobin Diosrders
5.2.2 Platelet Based Disorders
5.2.3 Plasma Disorders
5.2.4 Myeloproliferative Disorders
5.2.5 Genetic Hematology Disorders
5.2.6 Blood Cancers
5.2.7 Other Application
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Takeda Pharmaceutical Company Limited (Shire Plc)
6.1.2 Sanofi
6.1.3 Novo Nordisk A/S
6.1.4 CSL Ltd
6.1.5 Pfizer Inc
6.1.6 Bayer AG
6.1.7 Celgene Corporation
6.1.8 Alexion Pharmaceuticals, Inc
6.1.9 Amgen Inc
6.1.10 AstraZeneca Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS